Dallas, Texas, United States, November 02, 2021 (GLOBE NEWSWIRE) – Global Active Pharmaceutical Ingredients Market It is expected to reach $ 248.3 billion by 2027 from $ 187.3 billion in 2020, at a CAGR of 5.8% over the forecast period.
Two central components in the manufacture of a drug are APIs and excipients. API is the main component from which the drug is made, but the excipient is the ingredient that is not the drug, but acts as a medium that facilitates the intake of the drug by the body, such as lactose or mineral oil in a pill.
Request a sample copy of the research report: https://qualiketresearch.com/request-sample/Active-Pharmaceutical-Ingredient-API-Market/request-sample
Some of the major players operating in the active pharmaceutical ingredients (API) market are Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, Cipla, Inc., F. Hoffmann-La Roche AG , Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd.
Impact of COVID-19
The increase in corona cases around the world has played a critical role in the development of manufacturers of active pharmaceutical ingredients during the forecast period. The administration has performed molecule-by-molecule mapping of active pharmaceutical ingredients (APIs) imported from China to increase domestic build and third-party supplier imports given supply chain disruptions from the COVID-19 pandemic. The pandemic has added further difficulty as governments around the world have decided to boycott APIs made in China.
North America currently leads the market for active pharmaceutical ingredients and is expected to hold its place for a few more years due to the increasing incidence of disease and an aging population. The European regional market for active pharmaceutical ingredients is expected to represent a second major market share during the forecast period. The Asia-Pacific active pharmaceutical ingredients market is considered to be the most encouraging region in the global active pharmaceutical ingredients market due to the commoditization of emerging markets which are rapidly developing as hubs for outsourcing of the manufacture of drugs.
Get your personalized research report: https://qualiketresearch.com/request-sample/Active-Pharmaceutical-Ingredient-API-Market/ask-for-customization
In 2020, Pfizer (US) signed a multi-year agreement with Gilead Sciences to manufacture and supply Gilead’s antiviral drug (Remdesivir) for the treatment of COVID-19.
In 2020, Novartis (Switzerland) acquired the Japanese activities of Aspen to strengthen its position in the global market for generics and non-patent medicines. Novartis also has a manufacturing and supply agreement with Aspen.
In April 2020, Boehringer Ingelheim (Germany) acquired Northern Biologics, which focuses on therapeutic antibodies targeting the tumor microenvironment. This acquisition expanded Boehringer Ingelheim’s oncology product portfolio.
By economy mode
By type of synthesis
Through Drug type
- Other applications
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
Purchase this latest study report: https://qualiketresearch.com/paymentgateway/Active-Pharmaceutical-Ingredient-API-Market/payment-gateway
QualiKet Research is a leading market research and competitive intelligence partner that helps leaders around the world develop a strong strategy and stay ahead of the curve by providing actionable insights into Ever-changing market, competition and customer scenarios. QualiKet Research is dedicated to improving the ability to make faster decision-making by providing timely and scalable intelligence. We use different intelligence tools to provide evidence that highlights the threats and opportunities that help our clients outperform their competition.
Research support specialist
6060 N Central Expy # 500, TX 75204, United States
E-mail: [email protected]